NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-166-2022-0-EP-01 MYOTOMY CATHETER SYSTEM AND METHODS FOR A MYOTOMY CATHETER SYSTEM EP National Stage 23821091.8 Pending
NIAID E-234-2016-1-EP-01 PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE EP DIV 25180966.1 Pending
NCI E-248-2023-0-PC-01 FATTY ACID AND CYCLIZED DERIVATIVES OF THE IMMUNOMODULATORY PEPTIDE RP-182 WITH IMPROVED ANTI-TUMOR ACTIVITY, COMPOSITIONS, AND METHODS OF USE THEREOF PCT PCT PCT/US2025/032497 Pending
NEI E-028-2023-0-AU-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL
DEGENERATION 		AU National Stage 2023390868 Pending
NEI E-028-2023-0-JP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL
DEGENERATION 		JP National Stage 2025-555099 Pending
NIAID E-051-2023-0-US-02 HYDROGEL PURIFICATION OF CELL MATERIALS FOR PCR-ACTIVATED CELL SORTING US National Stage 19/135,423 Pending
NEI E-028-2023-0-US-02 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL
DEGENERATION 		US National Stage 19/135,668 Pending
NEI E-028-2023-0-CA-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL
DEGENERATION 		CA National Stage 3275801 Pending
NIAID E-025-2024-0-PC-01 PAN-GI NOROVIRUS MONOCLONAL ANTIBODY AND ITS USE PCT PCT PCT/US2025/031764 Pending
NCI E-185-2019-0-JP-01 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors JP DIV 2025-089701 Pending
NIAID E-028-2024-0-US-02 PEPTIDES AND PEPTIDE MICROARRAYS FOR DETECTION AND DIFFERENTIATION OF ANTIBODY RESPONSES TO EBOLA VIRUS US CON 19/220,639 Pending
NICHD E-185-2020-0-US-02 MULTIDIMENSIONAL MRI SIGNATURE FOR SPECIFIC DETECTION OF TRAUMATIC BRAIN INJURY IN VIVO US CON 19/220,496 Pending
NCI E-217-2023-0-PC-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PCT PCT PCT/US2025/031121 Pending
NCI E-206-2022-0-EP-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A EP National Stage 23814039.6 Pending
NCI E-213-2022-0-EP-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION EP National Stage 23809936.0 Pending
NCI E-190-2014-0-CN-01 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF
TUMORS 		CN DIV 202510674687.5 Pending
NIAID E-174-2023-0-KR-01 Self-Assembling Nanoparticles KR National Stage 10-2025-7016666 Pending
NIAID E-081-2013-4-AU-03 PREFUSION RSV F PROTEINS AND THEIR USE AU DIV 2025203614 Pending
NIAID E-033-2018-0-MO-01 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE MO CN J/009476 Issued
NCATS E-091-2016-0-BR-01 COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE BR DIV BR122025009773-0 Abandoned
NIAID E-135-2010-0-US-04 GENETICALLY STABLE LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE AND ITS PRODUCTION US CON 19/209,695 Abandoned
NCATS E-095-2018-0-CN-02 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS CN DIV 202510620323.9 Abandoned
NCI E-065-2024-0-PC-01 NATURAL KILLER CELLS EXPRESSING A MESOTHELIN-TARGETED CHIMERIC ANTIGEN
RECEPTOR AND INTERLEUKIN-15 FOR THE TREATMENT OF SOLID TUMORS 		PCT PCT PCT/US2025/029169 Pending
NIAID E-025-2023-0-EP-01 COMBINATION TREATMENT REGIMES FOR TREATING CANCER EP National Stage 23813192.4 Pending
CC E-158-2017-0-US-04 SYSTEMS, METHOD AND DEVICES FOR ASSISTING OR PERFORMING GUIDING INTERVENTIONAL PROCEDURES USING INERTIAL MEASUREMENT UNITS AND MAGNETOMETER SENSORS US CON 19/206,293 Pending
NCI E-239-2017-0-AU-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AU DIV 2025203455 Pending
NCATS E-114-2018-0-AU-01 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS AU DIV 2025203402 Pending
NCI E-201-2023-0-PC-01 QUANTITATIVE PARTICLE IDENTIFICATION DIGITAL AUTORADIOGRAPHY PCT PCT PCT/US2025/028714 Pending
NIAID E-174-2023-0-EP-01 Self-Assembling Nanoparticles EP National Stage 23809898.2 Pending
NCI E-033-2024-0-PC-01 CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-2 AND/OR CD276 AND THEIR USE FOR TREATING SOLID TUMORS PCT PCT PCT/US2025/028129 Pending
NHLBI E-166-2022-0-US-02 MYOTOMY CATHETER SYSTEM AND METHODS FOR A MYOTOMY CATHETER SYSTEM US National Stage 19/127,710 Pending
NEI E-126-2024-0-PC-01 CORYNEBACTERIUM MASTITIDIS-DERIVED MYCOLATES FOR TREATING BARRIERS PCT PCT PCT/US2025/027781 Pending
NIMH E-214-2023-0-PC-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION
THERAPY 		PCT PCT PCT/US2025/027755 Pending
NCI E-009-2023-0-US-02 IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OF CANCER AND MYELOID-MEDIATED DISEASES US National Stage 19/126,866 Pending
NIAID E-149-2022-0-US-02 NOVEL ANTIBODIES FOR HIV AND METHODS OF MAKING AND USING THE SAME US National Stage 19/126,308 Pending
NCATS E-095-2025-0-PC-01 Synthetic Superstolides and Therapeutic Use Thereof PCT PCT PCT/US2025/027113 Pending
NIAID E-041-2024-0-PC-01 ANTIBODIES AGAINST EV-D68 PCT PCT PCT/US2025/027110 Pending
NCATS E-001-2023-1-EP-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF EP National Stage 23875469.1 Pending
NCI E-016-2018-0-CN-01 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS CN DIV 202510544999.4 Pending
NHLBI E-223-2022-0-EP-01 PHYSIOLOGICAL NAVIGATION IN MRI USING INHERENT SLAB-SELECTIVE FREE-INDUCTION-DECAY SIGNAL EP National Stage 23793572.1 Pending
NCI E-167-2017-0-CN-01 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY CN DIV 202510520314.2 Pending
NCI E-237-2017-2-CR-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2025-0153 Pending
NCI E-029-2019-0-JP-01 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION JP DIV 2025-071352 Pending
NIAID E-025-2023-0-CA-01 COMBINATION TREATMENT REGIMES FOR TREATING CANCER CA National Stage 3271549 Pending
NCI E-181-2017-0-US-02 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US DIV 19/185,924 Pending
NCI E-028-2015-1-US-01 ANTI-MUTATED KRAS T CELL RECEPTORS US CON 19/185,602 Pending
NIA E-197-2022-0-US-02 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE US National Stage 19/122,658 Pending
NIAID E-025-2023-0-US-02 COMBINATION TREATMENT REGIMES FOR TREATING CANCER US CON 19/183,635 Pending
NIAID E-240-2023-0-CN-01 VACCINES AGAINST CORONAVIRUSES CN National Stage 202380073582.3 Pending
NIAID E-025-2023-0-AU-01 COMBINATION TREATMENT REGIMES FOR TREATING CANCER AU National Stage 2023367778 Pending